StarTric - A novel transcatheter medical device to treat Tricuspid Regurgitation

Objective

"Tricuspid Regurgitation (TR) poses a significant health challenge, affecting millions worldwide. Current treatment options, primarily open-heart surgery, come with inherent risks and are often unsuitable for frail patients. StarTric has pioneered a transcatheter device tailored to the intricate task of addressing TR. Drawing inspiration from the highly successful open-heart ""clover"" technique, this innovative device offers a minimally invasive alternative for TR repair. The StarTric device will reshape the tricuspid valve into a clover-like configuration, effectively restoring proper valve function. By replicating the efficacy of the clover procedure through transcatheter means, StarTric's solution holds immense promise in transforming the lives of countless patients globally. To bring this breakthrough solution to patients in need, StarTric requires funding support to accelerate development, clinical trials, regulatory approval and commercial efforts."